ASCO: Longer Tx Lengthens Life in GIST (CME/CE)
CHICAGO (MedPage Today) — Extending adjuvant imatinib (Gleevec) treatment for high-risk gastrointestinal stromal tumors (GIST) substantially boosts survival, researchers found.
CHICAGO (MedPage Today) — Extending adjuvant imatinib (Gleevec) treatment for high-risk gastrointestinal stromal tumors (GIST) substantially boosts survival, researchers found.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.